Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2004-05-26
2009-12-22
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S387100
Reexamination Certificate
active
07635472
ABSTRACT:
The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) or VH(CD3)-VL-(CD3)-VH(CD19)-VL(CD19). Processes for the production of the pharmaceutical compositions and medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are also disclosed.
REFERENCES:
patent: 5239062 (1993-08-01), Blattlick et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 7112324 (2006-09-01), Dorken et al.
patent: 2006/0193852 (2006-08-01), Dorken et al.
patent: 195 31 348 (1997-02-01), None
patent: 0 505 908 (1992-09-01), None
patent: 1293514 (2003-03-01), None
patent: WO 91/09968 (1991-07-01), None
patent: WO 95/11922 (1995-05-01), None
patent: WO 96/36360 (1996-11-01), None
patent: WO 99/54440 (1999-10-01), None
patent: WO 02/16414 (2002-02-01), None
ATCC entry for OKT3, 2009, 2 pages.
Peter M. Anderson et al., G19.4(αCD3)×R43(αCD19) Monuclonal Antibody Heteroconjugate Triggers CD19 Antigen-Specific Lysis of t(4;11) Acute Lymphoblastic Leukemia Cells by Activated CD3 Antigen-Positive Cytotoxic T Cells,Blood, vol. 80. No. 11 Dec. 1, 1992: pp. 2826-2834.
Heribert Bohlen et al., “Lysis of Malignant B Cells From Patients With B-Chronic Lymphocytic Leukemia by Autologous T Cells Activated With CD3×CD19 Bispecific Antibodies in Combination With Bivalent CD28 Antibodies,”Bloodvol. 82. No. 6 Sep. 15, 1993: pp. 1803-1812.
Heribert Bohlen et al., “Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies,”Cancer Research53. 4310-4314, Sep. 15, 1993.
Heribert Bohlen et al., “Prevention of Epstein-Barr Virus-induced Human B-Cell Lymphoma in Severe Combined Immunodeficient Mice Treated with CD3×CD19 Bispeciffc Antibodies, CD28 Monospecific Antibodies, and Autologous T Cells,”Cancer Research, 57: 1704-1709, May 1, 1997.
M. Cóska et al., “Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3×CD19 bispecific antibody,”Leukemia(1996) 10, 1765-1772.
Jan De Jonge et al., “Bispecific antibody treatment of murine B cell lymphoma,”Cancer Immunol Immunother(1997) 45:162-165.
Torsten Dreier et al., “Extremely Potent, Rapid And Costimulation-Independent Cytotoxic T-Cell Response Against Lymphoma Cells Catalyzed By A Single-Chain Bispecific Antibody,”Int. J. Cancer. 100, 000-000 (2002).
Inez-Anne Haagen et al., “Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispeciiic monoclonal antibody (αCD3/αCD19),”Clin. Exp. Immunol., (1992) 90, 368-375.
Inez-Anne Haagen et al., “Killing of Autologous B-Lineage Malignancy Using CD3×CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma,”Blood, vol. 84. No. 2 Jul. 15, 1994: pp. 556-563.
Inez-Anne Haagen et al., “Unprimed CD4+and CD8+T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic,”Cancer Immunol Immunother(1994) 39: 391-396.
Inez-Anne Haagen et al., “The Efficacy of CD3×CD19 Bispecific Monoclonal Antibody (BsAb) in a Clonogenic Assay: The Effect of Repeated Addition of BsAb and Interleukin-2,”Blood, vol. 85, No. 11 Jun. 1, 1995: pp. 3208-3212.
P. Kufer et al., “Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer,”Cancer Immunol Immunother(1997) 45: 193-197.
Peter Kufer et al., “Minimal costimulatory requirements for T cell priming and TH1 differentiation: Activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs,”Cancer Immunity1:10 (2001).
Anja Löffler et al., “A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes,”Blood, Mar. 15, 2000, vol. 95, No. 6.
Anja Löffler et al., “Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct,”Leukemia(2003) 17, 900-909.
Matthias Mack et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity,”Proc. Natl. Acad. Sci. USA, vol. 92, pp. 7021-7025, Jul. 1995.
Matthias Mack et al., “Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3, Tumor Cell-Dependent T Cell Stimulation and Cytotoxic Activity,”The Journal of Immunology, 1997, 158: 3965-3970.
George J. Weiner et al., “Bispecific Monoclonal Antibody Therapy of B -Cell Malignancy,”Leukemia and Lymphoma, vol. 16, pp. 199-207, 1995.
Dreier et al., “T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3-Bispecific Single-Chain Antibody Construct,” The Journal of Immunology, Apr. 15, 2003, vol. 170, No. 8, pp. 4397-4402.
Kipriyanov et al., “Bispecific CD3×CD19 diabody for T cell-mediated lysis of malignant human B cells,” International Journal of Cancer, Aug. 31, 1998, vol. 77, No. 4, pp. 763-771.
Kipriyanov et al., “Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics,” J. Mol. Biol., 1999, vol. 293, pp. 41-56.
Kipriyanov et al., “Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies,” J. Mol. Biol., Jun. 27, 2003, vol. 330, pp. 99-111.
Loeffler et al., “A recombinant bispecific single-chain antibody, CD19×CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes,” Blood, Mar. 15, 2000, vol. 95, No. 6, pp. 2098-2103.
Loeffler et al., “Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct,” Leukemia, May 2003, vol. 17, pp. 900-909.
Haagen, I., “Performance of CD3×CD19 Bispecific Monoclonal Antibodies in B Cell Malignancy,”Leukemia and Lymphoma, vol. 19, 1995, pp. 381-393.
Hayden, M.S., et al., “Single-chain Mono- and Bispecific Antibody Derivatives with Novel Biological Properties and Antitumour Activity from a COS Cell Transient Expression System,”Therapeutic Immunology, vol. 1, 1994, pp. 3-15.
Holliger, P., et al., “Diabodies: Small Bispecific Antibody Fragments,”Cancer Immunol. Immunother, vol. 45, 1997, pp. 128-130.
Kipriyanov, S.M., et al. “Rapid Detection of Recombinant Antibody Fragments Directed Against Cell-surface Antigens by Flow Cytometry,”J. of Immunological Methods, vol. 196, 1996, pp. 51-62.
Kipriyanov, S. M., et al., “Bispecific diabody for lysis of human B-lineage leukemia cells,” The Fourteenth International Conf. on Adv. In the Application of Monoclonal Antibodies in Clinical Oncology, May 5-7, 1997, Thira Santorini, Greece, p. 29.
Kostelny, S.A., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,”J. of Immunology, vol. 148, No. 5, 1992, pp. 1547-1553.
Kumar, P., et al.,Clinical Medicine, 3rd Edition, pp. 369-370, Bailliere Tindall, (Exhibit 3).
“National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphomas, Summary and Description of a Working Formulation for Clinical Usage,”Cancer, vol. 49, 1982, pp. 2112-2135, (Exhibit 1).
Olsen et al.,Hyb
Bauerle Patrick
Kohleisen Birgit
Kufer Peter
Lutterbuse Ralf
Zeman Steven
Foley & Lardner LLP
Micromet AG
Ouspenski Ilia
LandOfFree
Pharmaceutical compositions comprising bispecific anti-cd3,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising bispecific anti-cd3,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising bispecific anti-cd3,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4072373